United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

24 Oct 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CELG.OQ


Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)


Beta: 1.74
Market Cap(Mil.): $76,015.50
Shares Outstanding(Mil.): 775.11
Dividend: --
Yield (%): --


  CELG.OQ Industry Sector
P/E (TTM): 41.18 43.71 36.15
EPS (TTM): 2.38 -- --
ROI: 9.79 1.53 13.90
ROE: 32.45 0.83 14.83

BRIEF-Celgene & Sage Bionetworks use apple researchkit for observational study

* Celgene Corporation and Sage Bionetworks announce technology collaboration to develop observational study using the apple researchkit framework

Oct 18 2016

BRIEF-Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia

* Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML

Oct 12 2016

Amgen's multiple myeloma drug falls short in new-patient study

Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease.

Sep 27 2016

UPDATE 3-Amgen's multiple myeloma drug falls short in new-patient study

* Amgen stock down about 1.2 pct (Adds comments from conference call, analysts, details)

Sep 27 2016

BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial

* Celgene Corp -Oral Ozanimod efficacy and safety results at 2 years from Phase 2 RADIANCE trial of patients with relapsing multiple Sclerosis presented at 32nd Ectrims

Sep 16 2016

BRIEF-Sutro Biopharma receives 2 milestone payments from Celgene

* Sutro Biopharma Inc says financial terms of milestones are not being disclosed.

Sep 07 2016

BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib

* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)

Sep 07 2016

BRIEF-Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals

* Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing Source text: (http://bit.ly/2bBcQ6P) Further company coverage:

Aug 24 2016

BRIEF-Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources

* Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 29 2016

Sales of flagship drug Revlimid drive Celgene profit; forecast raised

NEW YORK Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.

Jul 28 2016


  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,743 -25.00
Eisai Co., Ltd (4523.T) ¥6,811 +6.00
Johnson & Johnson (JNJ.N) $113.61 +0.17
Novartis AG (NOVN.S) CHF73.60 -1.00
Pfizer Inc. (PFE.N) $32.13 -0.05
Roche Holding Ltd. (ROG.S) CHF230.10 -0.60
Roche Holding Ltd. (RO.S) CHF233.00 -0.60
Merck & Co., Inc. (MRK.N) $60.75 -0.45
Sanofi SA (SASY.PA) €69.44 +0.24
AstraZeneca plc (AZN.L) 4,858.50p +7.50

Earnings vs. Estimates